features: Trial Updates
FDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung…
Top 5 in lung from ASCO 2021
Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.
Key updates from EAU 2021
VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!
Top 5 in GI from ASCO 2021
VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
Top picks from ASCO 2021
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
Key updates from ESMO Breast 2021
VJOncology presents highlights from this year’s virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress!
St Gallen 2021 Highlights
VJOncology are excited to present some key abstracts and trial updates announced at this year’s virtual St. Gallen Breast Cancer…
WCLC 2021 Highlights
VJOncology are pleased to bring you our top picks from the recent virtual WCLC meeting
RxPONDER: sparing chemotherapy in post-menopausal patients with node-positive early-stage breast cancer
The de-escalation and treatment personalization of patients with early breast cancer has advanced in recent years, with studies such as…
Head and neck cancer updates presented at ESMO 2020
EPIC-OPC study: misclassification of OPC patients The presence of human papillomavirus p16 alone is not sufficient to classify oropharyngeal cancer…
ADAURA: osimertinib demonstrates significant clinical benefit in adjuvant NSCLC therapy
The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung…
TP53 mutations predict sensitivity to adjuvant chemotherapy in pancreatic cancers
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal malignancy and is often associated with a poor prognosis. Surgery remains…